


Phase 3, Randomized, Open-Label Study of Pembrolizumab Versus Brentuximab Vedotin for Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma: KEYNOTE-204



P. L. Zinzani¹; R. Ramchandren²; A. Santoro³; E. Paszkiewicz-Kozik⁴; R. Gasiorowski⁵;
N. A. Johnson⁶; V. Melnichenko⁷; L. M. Fogliatto⁸; I. Goncalves⁹; J. S. R. de Oliveira¹⁰;
V. Buccheri¹¹; G. Fleury Perini¹²; N. Goldschmidt¹³; S. Alekseev¹⁴; I. Kriachok¹⁵; N.
Sekiguchi¹⁶; Y. Zhu¹⁷; A. Nahar¹⁷; P. Marinello¹⁷; J. Kuruvilla¹⁸

¹Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; ²The University of Tennessee, Knoxville, TN, USA; ³Humanitas Clinical and Research Center, IRCCS, Milan, Italy; ⁴Maria Skłodowska-Curie National Institute of Oncology, Warsaw, Poland; ⁵Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia; ⁶Jewish General Hospital, Montreal, QC, Canada; ⁷Pirogov National Medical and Surgical Center, Moscow, Russia; ⁸Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; ⁹Fundação Pio XII – Hospital de Câncer, São Paulo, Brazil; ¹⁰Casa de Saúde Santa Marcelina, São Paulo, Brazil; ¹¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; ¹²Hospital Israelita Albert Einstein, São Paulo, Brazil; ¹³Hadassah Medical Center, Jerusalem, Israel; ¹⁴N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; ¹⁵National Cancer Institute, Ukraine, Kiev, Ukraine; ¹⁶National Hospital Organization Disaster Medical Center, Tokyo, Japan; ¹⁷Merck & Co., Inc., Kenilworth, NJ, USA; ¹⁸Princess Margaret Cancer Centre, Toronto, ON, Canada


KEYNOTE-204 Study Design (NCT02684292)



¹. Cheson BD et al. *J Clin Oncol*. 2007;25:579-586.

Primary End Point: Progression-Free Survival per Blinded Independent Central Review

Including clinical and imaging data following auto-SCT or allo-SCT



	Events n (%)	HR (95% CI)	P value
Pembro	81 (53.6)	0.65 (0.48-0.88)	0.00271
BV	88 (57.5)		


No. at risk

	0	3	6	9	12	15	18	21	24	27	30	33	36	39
Pembro	151	116	96	74	65	55	44	35	18	15	9	4	1	0
BV	153	103	63	41	32	26	19	14	10	7	5	2	1	0

Data cutoff: January 16, 2020

Progression-Free Survival per Blinded Independent Central Review

Excluding clinical and imaging data following auto-SCT or allo-SCT




No. at risk

Pembro	151	112	87	65	56	48	37	30	16	11	5	2	1	0
BV	153	98	58	39	30	23	17	13	10	4	4	1	0	0


Data cutoff: January 16, 2020

Treatment-Related AEs ($\geq 10\%$ Either Arm)



Data cutoff: January 16, 2020

Immune-Mediated AEs



Based on a list of terms specified by the sponsor and included by the investigator regardless of attribution to study treatment or immune relatedness.
 Data cutoff: January 16, 2020